Experimental repurposing of metformin for Crohn’s disease in trinitrobenzene sulfonic acid induced colitis model in BALB/c mice

Chetan N. Phirke; Harshal J. Visaria; Shruti S. Bhide; Rahul S. Kothari; Saurabh R. Patil; Neha M. Abhyankar

doi:10.18203/2319-2003.ijbcp20243839

Authors

Chetan N. Phirke Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Harshal J. Visaria Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Shruti S. Bhide Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Rahul S. Kothari Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Saurabh R. Patil Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Neha M. Abhyankar Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243839

Keywords:

Colitis, BALB/c mice, Acute on chronic anti-inflammatory

Abstract

Background: Inflammatory bowel disease (IBD) is characterized by repetitive episodes of inflammation of the gastrointestinal tract caused by an abnormal immune response to gut microflora. It includes two types: Ulcerative colitis (UC), which causes widespread colon inflammation, and Crohn’s disease (CD). The current therapy focuses on symptom relief and provides inadequate maintenance of remission and quality of life improvement. Metformin has already been repurposed in few studies with dextran sulphate sodium (DSS) induced colitis. We aimed to evaluate the effect of metformin in TNBS induced acute on chronic colitis, to mimic the relapsing-remitting nature of CD in humans, which has not been done before.

Methods: Objectives were, phase I- evaluation of the effect of metformin in TNBS induced acute colitis in BALB/c mice. Phase II- evaluation of the effect of metformin in TNBS induced chronic colitis in BALB/c mice. Phase III- Evaluation of the effect of metformin in TNBS induced acute on chronic colitis in BALB/c mice. Materials And Methods: Trinitrobenzene sulfonic acid (TNBS) was used for inducing both acute, chronic and acute on chronic colitis in BALB/c mice. 36 BALB/c mice were divided into 4 groups i.e. normal control, disease control, positive control and test drug. Effect on DAI score, lower colon weight by length ratio, macroscopy and histopathology were assessed.

Results: Metformin showed significant improvement (p<0.05) in all the variables assessed i.e. reduction of (Disease Activity Index) DAI score, lower colon weight by length ratio, lower colon macroscopic score and lower histopathological score in comparison to the disease control group in all the phases i.e. acute (day 5), chronic (day 22) and acute on chronic (day 25). However, the effects were comparable to the positive control.

Conclusions: Metformin has potential to be repurposed for Crohn’s disease as it showed comparable efficacy in all three phases.

Metrics

Metrics Loading ...

References

Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. Handb Exp Pharmacol. 2017;239:115–46.

Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021;2:100070.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517.

Prattichizzo F, Giuliani A, Mensà E, Sabbatinelli J, De Nigris V, Rippo MR, et al. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018;48:87–98.

Di Fusco D, Dinallo V, Monteleone I, Laudisi F, Marafini I, Franzè E, et al. Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clin Sci. 2018;132(11):1155–68.

Chen L, Wang J, You Q, He S, Meng Q, Gao J. Activating AMPK to restore tight junction assembly in intestinal epithelium and to attenuate experimental colitis by metformin. Frontiers in Pharmacology. 2018. Available at: https://www.frontiersin.org/articles. Accessed on 23 August 2024.

Gadaleta RM, Garcia-Irigoyen O, Moschetta A. Exploration of inflammatory bowel disease in mice: chemically induced murine models of inflammatory bowel disease (IBD): Chemically Induced Murine Models of IBD. Curr Pro in Mouse Bio. 2017;7(1):13–28.

Goyal N, Rana A, Ahlawat A, Bijjem KRV, Kumar P. Animal models of inflammatory bowel disease: a review. Inflammopharmacol. 2014;22(4):219–33.

Wang SQ, Cui SX, Qu XJ. Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice. Cancer Biol Ther. 2019;20(3):338-48.

Takahara M, Takaki A, Hiraoka S, Takei K, Yasutomi E, Igawa S, et al. Metformin ameliorates chronic colitis in a mouse model by regulating interferon-γ-producing lamina propria CD4+ T cells through AMPK activation. FASEB J. 2022;36(2):22139.

Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immunol. 2002;15:19.

Dohi T, Fujihashi K. Type 1 and 2 T helper cell-mediated colitis: Curr Opin Gastroenterol. 2006;22(6):651–7.

Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol. 2007;13(42):5581–93.

Axelsson LG, Landström E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther. 1998;12(9):925-34.

Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, et al. The TNBS-induced colitis animal model: An overview. Ann Med Surg. 2016;11:9–15.

Sasaki M. Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radical Biology and Medicine. 2003;35(12):1679–87.

Inokuchi Y. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut. 2005;54(3):349–56.

Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SGM, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114(3):385–91.

Liu X, Sun Z, Wang H. Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. Biotech Histochem. 2021;96(2):146–52.

Koh SJ, Kim JM, Kim IK, Ko SH, Kim JS. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. Journal of Gastroenterology and Hepatology. 2014;29(3):502–10.

Pandey A, Verma S, Kumar VL. Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling. Biomed Pharmacoth. 2017;94:1121–8.

El-Mahdy NA, El-Sayad MES, El-Kadem AH, Abu-Risha SES. Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway. Immunopharmacol Immunotox. 2021;43(2):192–202.

Stadnicki A, Colman RW. Experimental models of inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 2003;51(3):149–55.

Dothel G, Vasina V, Barbara G, De Ponti F. Animal models of chemically induced intestinal inflammation: predictivity and ethical issues. Pharmacol Ther. 2013;139(1):71–86.

Mariman R, Kremer B, Erk M, Lagerweij T, Koning F, Nagelkerken L. Gene expression profiling identifies mechanisms of protection to recurrent trinitrobenzene sulfonic acid colitis mediated by probiotics. Inflamm Bowel Dis. 2012;18(8):1424–33.

Wang YH, Ge B, Yang XL, Zhai J, Yang LN, Wang XX, et al. Proanthocyanidins from grape seeds modulates the nuclear factor-kappa B signal transduction pathways in rats with TNBS-induced recurrent ulcerative colitis. Int Immunopharmacol. 2011;11(10):1620–7.

Arab HH, Al-Shorbagy MY, Saad MA. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. Chemico-Biological Interactions. 2021;335:109368.

El-Rous MA, Saber S, Raafat EM, Ahmed AAE. Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis. Inflammopharmacol. 2021;29(4):1169–85.